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ORIGINAL RESEARCH
Legumain in Acute Coronary Syndromes: A 
Substudy of the PLATO (Platelet Inhibition 
and Patient Outcomes) Trial
Ida Gregersen , PhD; Annika E. Michelsen, PhD; Ngoc Nguyen Lunde , PhD; Axel Åkerblom, MD, PhD; 
Tatevik G. Lakic , MSc; Mona Skjelland, MD, PhD; Karolina Ryeng Skagen, MD, PhD; Richard C. Becker, MD; 
Johan Lindbäck , PhLic; Anders Himmelmann, MD, PhD; Rigmor Solberg, PhD; Harald T. Johansen , PhD; 
Stefan K. James, MD, PhD; Agneta Siegbahn, MD, PhD; Robert F. Storey, MD, DM; Frederic Kontny, MD, PhD; 
Pål Aukrust, MD, PhD; Thor Ueland, PhD; Lars Wallentin, MD, PhD; Bente Halvorsen, PhD
BACKGROUND: The cysteine protease legumain is increased in patients with atherosclerosis, but its causal role in atherogenesis 
and cardiovascular disease is still unclear. The aim of the study was to investigate the association of legumain with clinical 
outcome in a large cohort of patients with acute coronary syndrome.
METHODS AND RESULTS: Serum levels of legumain were analyzed in 4883 patients with acute coronary syndrome from a 
substudy of the PLATO (Platelet Inhibition and Patient Outcomes) trial. Levels were analyzed at admission and after 1 month 
follow-up. Associations between legumain and a composite of cardiovascular death, spontaneous myocardial infarction or 
stroke, and its individual components were assessed by multivariable Cox regression analyses. At baseline, a 50% increase 
in legumain level was associated with a hazard ratio (HR) of 1.13 (95% CI, 1.04–1.21), P=0.0018, for the primary composite 
end point, adjusted for randomized treatment. The association remained significant after adjustment for important clinical and 
demographic variables (HR, 1.10; 95% CI, 1.02–1.19; P=0.013) but not in the fully adjusted model. Legumain levels at 1 month 
were not associated with the composite end point but were negatively associated with stroke (HR, 0.62; 95% CI, 0.44–0.88; 
P=0.0069), including in the fully adjusted model (HR, 0.57; 95% CI, 0.37–0.88; P=0.0114).
CONCLUSIONS: Baseline legumain was associated with the primary outcome in patients with acute coronary syndrome, but not 
in the fully adjusted model. The association between high levels of legumain at 1 month and decreased occurrence of stroke 
could be of interest from a mechanistic point of view, illustrating the potential dual role of legumain during atherogenesis and 
acute coronary syndrome.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT00391872.
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A
therosclerosis, a progressive pathological pro-
cess with build-up of intimal plaque in the artery 
wall, is the main cause of cardiovascular disease. 
Atherosclerosis is characterized by nonresolving in-
flammation and both immune and vascular cells ex-
press and release an enormous amount of mediators 
affecting the rate and course of plaque progression, in-
cluding the development of acute coronary syndrome 
(ACS) and ischemic stroke.1
Legumain, also known as asparagine endopepti-
dase, is a member of the C13 family of cysteine prote-
ases.2 It has broad immunoregulatory properties such 
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as toll-like receptor modulation,3 processing of anti-
gens for major histocompatibility complex class II pre-
sentation,4 monocyte chemotaxis,5 induction of Th1 
cell responses,6 and regulation of extracellular matrix 
remodeling.7,8 Legumain is expressed in both murine 
and human atherosclerotic lesions,5 and in patients 
with carotid stenosis we found increased legumain 
levels in plasma and plaques, with the highest expres-
sion in lesions from symptomatic patients.9 Further, it 
was recently shown that legumain induced vascular 
remodeling in atherosclerosis-prone ApoE−/− mice by 
increasing the number of macrophages and vascu-
lar smooth muscle cells within the atherosclerotic le-
sions.10 Based on these findings, we hypothesized that 
legumain could be released during plaque destabiliza-
tion and contribute to myocardial and vascular remod-
eling following ACS.
To further explore this hypothesis, legumain levels 
were analyzed in a large population of patients with 
ACS from the PLATO (Platelet Inhibition and Patient 
Outcomes) trial, encompassing a broad spectrum 
of ACS events. Legumain levels were analyzed on 
admission and after 1 month of follow-up after ACS, 
together with established prognostic biomarkers, 
and related to fatal and nonfatal cardiovascular 
outcomes.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Design and Study Population
The PLATO trial (NCT00391872) was a randomized, 
placebo-controlled trial including 18 624 patients with 
ACS. The patients presented with either ST-elevation 
ACS or non ST-elevation ACS and were randomized 
to either clopidogrel or ticagrelor treatment in addition 
to optimal medical therapy, including aspirin, and op-
tional invasive therapy.11,12 The patients were recruited 
between October 2006 and July 2008 and were fol-
lowed for up to 12 months after ACS.
Venous blood samples were obtained from all pa-
tients at randomization as part of the main study. In 
addition, there was a predefined substudy with serial 
blood sampling conducted at selected sites at dis-
charge and after 1 and 6 months.11,13 The overall aims 
of this biomarker substudy program have previously 
been published.11–13 Patients with a blood sample at 
baseline and additional blood sample during 1-month 
follow-up, with no new cardiovascular event before the 
date of the 1-month sample, were eligible for inclusion 
in the current analyses. Informed consent was ob-
tained from all patients included and the trial complied 
with national and institutional regulatory and ethics 
committees and the Declaration of Helsinki. A detailed 
description of Sampling and Laboratory analysis can 
be found in Data S1.
End Point Definition and Follow-Up
The prespecified primary end point of the present 
substudy was the composite of cardiovascular death 
(defined as any cardiovascular cause of death, sud-
den death, or any death with no clear attributable 
noncardiovascular cause), spontaneous myocardial 
infarction (defined as non-procedure-related, nonfa-
tal, MI type 1)14 or stroke within 1 year of follow-up.11 
Secondary outcomes were procedural MI, stroke and 
major bleeding not related to coronary artery bypass 
graft (CABG) surgery, either fatal, intracranial, or re-
quiring ≥ 2 units of blood transfusion or with a drop in 
hemoglobin of> 5 g/dL.11 All end points in the PLATO 
trial were centrally adjudicated by an independent and 
blinded clinical event adjudication committee, com-
prising cardiologists or neurologists, in order to sub-
classify causes of death and to subdivide types of MIs, 
stroke, or bleeding events.11,14
CLINICAL PERSPECTIVE
What Is New?
• Legumain has previously been shown to be up-
regulated in carotid atherosclerotic plaques and 
associated with mortality in patients with ST-
segment–elevation myocardial infarction.
• In this study, legumain is evaluated as a prog-
nostic biomarker in a large population with 
acute coronary syndrome.
What Are the Clinical Implications?
• Legumain was associated with worse outcomes 
in patients with acute coronary syndrome but 
not in the fully adjusted model.
• Legumain levels at 1 month was negatively as-
sociated with occurrence of stroke.
• The association between high levels of legu-
main at 1 month and decreased occurrence of 
stroke could be of interest from a mechanistic 
point of view, illustrating the complex and po-
tential dual role of legumain during acute coro-
nary syndrome and atherogenesis.
Nonstandard Abbreviations and Acronyms
CABG coronary artery bypass graft
PLATO Platelet Inhibition and Patient Outcomes
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Statistical Analysis
Baseline characteristics and patient demographics 
were compared between legumain quartile groups 
using Kruskal-Wallis tests for continuous variables 
and chi-square tests for categorical variables. The 
Kruskal-Wallis test was used as it has high power 
when the normality assumption is not fulfilled and does 
not lose much power even if the normality assump-
tion holds. Biomarkers were logarithmic-transformed 
when appropriate. Multivariable regression assessed 
the relationship between legumain and baseline char-
acteristics, with legumain as the depending variable. 
We calculated geometric means using the antiloga-
rithms of the model-adjusted means (ie, predicted 
marginal means), and subsequently compared geo-
metric means between groups (eg, males/females) 
using ratios. The unadjusted association between 
legumain quartile groups and clinical outcomes were 
presented by Kaplan-Meier curves. Cox proportional 
hazards models were used to investigate the covar-
iate-adjusted association between legumain and the 
composite end point of cardiovascular death, spon-
taneous MI, or stroke and secondary outcomes: pro-
cedural MI, stroke, and non-CABG major bleeding. 
Five models, with incremental addition of covariates, 
were used. Model 0 included legumain and rand-
omized treatment (ticagrelor or clopidogrel). Model 1a 
added age, sex, body mass index, diabetes mellitus, 
dyslipidemia, hypertention, chronic renal disease, 
chronic heart failure, ST-segment–elevation myocar-
dial infarction (STEMI)/non–ST-segment–elevation-
ACS at randomization, smoking, type of ACS, aspirin 
at entry, history of MI, percutaneous coronary inter-
vention, CABG, stroke, or peripheral artery disease. 
Model 1b included the following covariates in addition 
to Model 1a: unfractionated heparin, low-molecular-
weight heparin, use of glycoprotein IIb/IIIa inhibitor, 
statin, diuretic, and proton pump inhibitor during 
hospital stay. Model 1c included the following covari-
ates in addition to Model 1b: hemoglobin, platelets, 
and white blood cell count. Model 2 further added 
C-reactive protein; Model 3, cystatin C; Model 4, 
NT-proBNP (N-terminal-pro-B-type natriuretic pep-
tide) and TnT (troponin T); and Model 5 included all 
variables in addition to GDF-15 (growth differentiation 
factor 15). All biomarkers were included as continu-
ous variables after logarithmic transformation. The 
results were presented as the relative hazard for 50% 
increase in legumain concentration at baseline. The 
proportional hazards assumption was assessed by 
visual inspection of Schoenfeld residual plots. The 
association between legumain levels and clinical 
outcomes were illustrated by restricted cubic splines 
with 4 knots placed at the 5th, 35th, 65th, and 95th 
sample percentiles.
A statement of statistical significance implies a 
P value of <0.05 and there were no adjustments for 
multiple comparisons. All statistical analyses were per-
formed with SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
Legumain at Admission in Relation to 
Baseline Characteristics
Compared to the total PLATO population, the base-
line characteristics of the current substudy showed a 
similar pattern except for more frequent STEMI, less 
frequent diabetes mellitus, and lower high-sensitiv-
ity TnT and NT-proBNP (Table S1). Legumain levels 
at admission were available in 4883 patients with a 
median (Q1-Q3) of 2.78 (1.97–3.86) ng/mL. Baseline 
characteristics by legumain quartile groups are pre-
sented in Table 1. In multivariable analysis of baseline 
characteristic, the strongest correlations with legu-
main were age, STEMI, use of glycoprotein IIb/IIIa 
inhibitor, GDF-15, and platelet count (P<0.001 for all; 
Table S2).
Association of Baseline Legumain Levels 
With Clinical Outcomes
Of the 4883 patients included, the primary compos-
ite end point (cardiovascular death/spontaneous MI/
stroke) was observed in 421 individuals, with an event 
rate of 8.6%. Baseline legumain levels (with hazard 
ratio [HR] per 50% increase of legumain) were as-
sociated with the primary composite end point (HR, 
1.13; 95% CI, 1.04–1.21; P=0.0018) after adjusting for 
randomized treatment, Model 0 (Table 2). Kaplan-
Meyer estimates per quartile of baseline legumain 
levels are presented in Figure  1A, showing a posi-
tive association with the primary composite end 
point. Restricted cubic spline curves for legumain 
at baseline against different outcomes are shown in 
Figure  1B. In multivariable Cox regression analyses 
(Table 2), the association between baseline legumain 
and the primary composite end point remained as-
sociated after adjustment for important clinical and 
demographic variables (Model 1a; HR, 1.13; 95% CI, 
1.05–1.22; P=0.0021) and the use of medication (ie, 
statins, diuretics, use of glycoprotein IIb/IIIa inhibi-
tor, Model 1b; HR, 1.10; 95% CI, 1.02–1.19; P=0.013). 
However, these associations were attenuated after 
further adjustment for hemoglobin, platelets, white 
blood cell count, C-reactive protein, cystatin C, NT-
proBNP, TnT, and GDF-15 (Model 1c-5; HR 1.08; 95% 
CI, 0.99–1.17; P=0.0747). There were no associations 
between baseline legumain levels and the rand-
omized treatment regimen (ie, clopidogrel or ticagre-
lor, Figure S1) on any end point (Table 2).
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Table 1. Baseline Characteristics of Study Participants According to Legumain Quartiles (N=4883)
Characteristics*
Q1 <1.97 ng/mL 
n=1219
Q2 1.97–2.78 
ng/mL 
n=1225
Q3 2.78–3.86 
ng/mL 
n=1218
Q4 >3.86 ng/mL 
n=1221 P Value†
Demographics
Age, y 63 (54–71) 63 (54–71) 63 (54–71) 61 (53–69) 0.0017
Female 385 (31.6%) 395 (32.2%) 357 (29.3%) 330 (27.0%) 0.0204
Weight, kg 80 (70–90) 80 (70–90) 81 (71–91) 80 (70–90) 0.0223
Body mass index, kg/m2 27.3 (24.9–30.2) 27.5 (24.8–30.5) 27.7 (25.2–30.9) 27.8 (25.2–31.0) 0.0116
Risk factors
Habitual smoker 437 (35.8%) 437 (35.7%) 422 (34.6%) 485 (39.7%) 0.0491
Hypertension 759 (62.3%) 808 (66.0%) 816 (67.0%) 845 (69.2%) 0.0033
Dyslipidemia 509 (41.8%) 513 (41.9%) 538 (44.2%) 497 (40.7%) 0.3617
Diabetes mellitus 228 (18.7%) 245 (20.0%) 294 (24.1%) 332 (27.2%) <.0001
Medical history
Angina pectoris 505 (41.4%) 571 (46.6%) 604 (49.6%) 598 (49.0%) 0.0002
Myocardial infarction 189 (15.5%) 240 (19.6%) 267 (21.9%) 269 (22.0%) <.0001
Congestive heart failure 51 (4.2%) 54 (4.4%) 81 (6.7%) 98 (8.0%) <.0001
Percutaneous coronary 
intervention
124 (10.2%) 155 (12.7%) 159 (13.1%) 169 (13.8%) 0.0379
Coronary artery bypass graft 46 (3.8%) 59 (4.8%) 67 (5.5%) 70 (5.7%) 0.1115
Transient ischemic attack 23 (1.9%) 23 (1.9%) 42 (3.4%) 25 (2.0%) 0.0252
Nonhemorrhagic stroke 33 (2.7%) 43 (3.5%) 45 (3.7%) 44 (3.6%) 0.5106
Peripheral arterial disease 59 (4.8%) 71 (5.8%) 97 (8.0%) 108 (8.8%) 0.0002
Chronic renal disease 49 (4.0%) 42 (3.4%) 44 (3.6%) 37 (3.0%) 0.6110
Thrombolysis in myocardial 
infarction risk score
4 (2–5) 4 (2–5) 4 (2–5) 4 (3–5) <.0001
Global Registry of Acute Coronary 
Events risk score
136 (121–153) 133 (117–150) 134 (117–151) 133 (115–151) 0.0185
Type of acute coronary syndrome 
ST-elevation myocardial infarction
710 (58.2%) 558 (45.6%) 459 (37.7%) 458 (37.5%) <0.0001
In hospital medication
Aspirin 1206 (98.9%) 1205 (98.4%) 1192 (97.9%) 1198 (98.1%) 0.2012
Unfractioned heparin 736 (60.4%) 657 (53.6%) 638 (52.4%) 628 (51.4%) <0.0001
Low-molecular-weight heparin 600 (49.2%) 676 (55.2%) 694 (57.0%) 672 (55.0%) 0.0008
Fondaparinux 12 (1.0%) 21 (1.7%) 19 (1.6%) 21 (1.7%) 0.3897
Bivalirudin 14 (1.1%) 15 (1.2%) 19 (1.6%) 27 (2.2%) 0.1281
Glycoprorein IIb/IIIa inhibitor 426 (34.9%) 318 (26.0%) 281 (23.1%) 246 (20.1%) <.0001
Beta blocker 1081 (88.7%) 1059 (86.4%) 1060 (87.0%) 1054 (86.3%) 0.2800
Angiotensin-converting inhibitor 
and/or angiotensin receptor 
blocker
1043 (85.6%) 1069 (87.3%) 1069 (87.8%) 1056 (86.5%) 0.3992
Cholesterol lowering (statin) 1166 (95.7%) 1162 (94.9%) 1131 (92.9%) 1104 (90.4%) <0.0001
Ca-inhibitor 251 (20.6%) 263 (21.5%) 255 (20.9%) 259 (21.2%) 0.9575
Diuretic 408 (33.5%) 436 (35.6%) 473 (38.8%) 530 (43.4%) <0.0001
Proton pump inhibitor 598 (49.1%) 537 (43.8%) 506 (41.5%) 485 (39.7%) <0.0001
Biomarkers
Hemoglobin 140 (130–149) 140 (130–149) 143 (132–153) 143 (133–153) <0.0001
Platelets 223 (190–262) 227 (191–270) 236 (202–276) 246 (207–292) <0.0001
White blood cells 9.6 (7.4–11.9) 9.1 (7.4–11.3) 9.1 (7.3–11.3) 9.5 (7.5–11.6) 0.0123
Neutrophils 7.0 (5.0–9.4) 6.6 (4.9–8.7) 6.6 (4.8–8.7) 6.7 (4.9–9.0) 0.0010
Monocytes 0.4 (0.2–0.6) 0.4 (0.2–0.6) 0.4 (0.3–0.6) 0.5 (0.3–0.7) <0.0001
 (Continued)
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Association of Legumain Levels at  
Follow-Up With Clinical Outcomes
The distribution of legumain levels was higher at dis-
charge compared with baseline, followed by a slight 
decline reaching steady state levels at 1 month with 
similar levels at 6 months (Figure  2A), with no dif-
ferences in levels between the treatment groups 
(Figure  2B). Follow-up measurements at 1 month 
were available from 3927 patients of whom 228 
(event rate 5.8%) suffered a primary composite end 
point (cardiovascular death/spontaneous MI/stroke). 
The numbers of strokes, procedural MIs, and non-
CABG-related major bleeds (secondary end points) 
were 34 (0.9%), 25 (0.6%) and 69 (1.8%), respectively. 
Legumain at 1 month follow-up (with HR per 50% in-
crease of legumain) was not statistically significantly 
associated with the composite primary outcome, 
procedural MI, or non-CABG-related major bleeds 
but was negatively associated with stroke (HR, 0.62; 
95% CI, 0.44–0.88; P=0.0069; Model 0, adjusted 
for randomized treatment). The association between 
legumain levels at 1 month and different outcomes is 
shown in Figure S2. In multivariable Cox regression 
analyses this association with stroke remained sta-
tistically significant when adjusting for all covariates, 
including C-reactive protein, cystatin C, NT-proBNP, 
TnT, and GDF-15, that are shown to have a significant 
prognostic power in this population15 (HR, 0.57; 95% 
CI, 0.37–0.88; P=0.0114 [Model 5, Table 3]).
DISCUSSION
Legumain has previously been shown to be up-
regulated in carotid atherosclerotic plaques, with the 
highest levels in those with symptomatic lesions.9 
Moreover, legumain levels are shown to be associated 
with complex coronary lesions,16 and we have recently 
shown that low legumain levels were associated with 
mortality (univariate analyses) in a small population of 
patients with STEMI (n=272).17 The present study is, 
however, to the best of our knowledge, the first study 
that evaluates legumain as a prognostic biomarker in a 
large population with ACS (n=4883). Although baseline 
legumain levels were significantly associated with the 
primary end point after adjusting for important demo-
graphic and clinical factors (eg, age, sex, body mass 
index, diabetes mellitus) and use of medications, this 
association was not significant in the full model adjust-
ing for biomarkers including C-reactive protein, TnT, 
cystatin C, GDF-15, and NT-proBNP. These findings 
suggest that although legumain is upregulated in pa-
tients with ACS, it does not give additional prognostic 
information beyond the established biomarkers.
The role of legumain in atherogenesis and acute 
cardiovascular events is at present not clear. Legumain 
is shown to induce vascular smooth muscle cells mi-
gration and atherosclerotic vascular remodeling, driv-
ing atherosclerotic plaque development.10 However, 
our previous findings illustrate that legumain also may 
have plaque stabilizing and anti-atherogenic proper-
ties.17 Further, whereas legumain has been reported to 
promote an inflammatory M1 phenotype and foam cell 
formation in macrophages,10 we have recently shown 
that legumain also can induce an anti-inflammatory 
macrophage phenotype.17 Furthermore, legumain has 
been shown to mediate effects of M2 macrophages 
in a mouse model of obstructive nephropathy18 and 
to promote pulmonary artery hypertension through 
induction of transforming growth factor ž19. Although 
transforming growth factor ž signaling could be 
harmful in fibrotic disorders, it could potentially sta-
bilize the plaque phenotype in atherosclerotic lesions. 
Interestingly, we have shown that legumain is released 
from platelets and macrophages and colocalized with 
these cells in carotid atherosclerotic plaques as well 
as in thrombi from patients with STEMI and patients 
with ischemic stroke.17 This suggests that legumain is 
Characteristics*
Q1 <1.97 ng/mL 
n=1219
Q2 1.97–2.78 
ng/mL 
n=1225
Q3 2.78–3.86 
ng/mL 
n=1218
Q4 >3.86 ng/mL 
n=1221 P Value†
Lymphocytes 1.7 (1.3–2.2) 1.8 (1.3–2.3) 1.8 (1.4–2.3) 1.9 (1.4–2.4) <0.0001
Troponin T, ng/L 124.0 (35.1–420.0) 152.5 
(43.5–468.5)
180.0 
(37.4–604.0)
195.0 (42.8–692.0) <0.0001
N-terminal pro-B-type natriuretic 
peptide, pmol/L
280.0 (97.0–865.0) 398.0 
(129.0–998.0)
478.5 
(149.5–1248)
546.0 (192.5–1565) <0.0001
Cystatin C, mg/L 0.78 (0.63–0.94) 0.81 (0.66–0.99) 0.83 (0.69–1.00) 0.86 (0.71–1.06) <0.0001
Growth differentiation factor 15, 
ng/mL
1454 (1076–1992) 1508 
(1136–2082)
1535 (1158–2148) 1699 (1229–2471) <0.0001
C-reactive protein, mg/L 2.6 (1.2–5.8) 3.2 (1.5–7.7) 3.7 (1.6–9.3) 5.4 (2.1–14.0) <0.0001
Interleukin-6, ng/mL 2.9 (1.7–5.2) 3.1 (1.9–6.7) 3.6 (2.0–8.1) 4.2 (2.2–9.5) <0.0001
*Continuous variables are expressed median (interquartile range). Categorical variables are expressed as frequency (%).
†P values from the chi-square test (categorical variables) or Kruskal-Wallis test (continuous variables).
Table 1. Continued
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Table 2. Effect of Baseline Legumain on Outcomes (N=4883)
Cardiovascular Death/Spontaneous  
MI/Stroke Stroke† Procedural MI Non-CABG-Related Major Bleeds
N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value||
Model 0* 421 (8.6) 1.13 (1.04–1.21) 0.0018 59 (1.2) 0.97 (0.80–1.18) 0.7711 94 (1.9) 0.96 (0.82–1.12) 0.5733 185 (3.8) 1.00 (0.90–1.12) 0.9641
Model 1a* 419 (8.6) 1.13(1.05–1.22) 0.0021 59 (1.2) 0.96 (0.78–1.18) 0.6951 93 (1.9) 0.92 (0.79–1.09) 0.3388 184 (3.8) 1.02 (0.91–1.14) 0.7645
Model 1b* 419 (8.6) 1.10 (1.02–1.19) 0.013 59 (1.2) 0.93 (0.76–1.15) 0.5215 93 (1.9) 0.94 (0.80–1.11) 0.4621 184 (3.8) 1.03 (0.91–1.15) 0.6510
Model 1c* 375 (8.5) 1.08 (0.99–1.17) 0.0747 53 (1.2) 0.97 (0.77–1.21) 0.7718 86 (1.9) 0.91 (0.77–1.08) 0.2945 159 (3.6) 1.02 (0.90–1.16) 0.7248
Model 2* 350 (8.7) 1.06 (0.97–1.16) 0.2166 47 (1.2) 0.91 (0.72–1.15) 0.4312 79 (2.0) 0.86 (0.72–1.03) 0.1110 150 (3.7) 1.03 (0.90–1.18) 0.6482
Model 3* 350 (8.7) 1.06 (0.97–1.15) 0.2314 47 (1.2) 0.91 (0.72–1.15) 0.4374 79 (2.0) 0.86 (0.72–1.03) 0.1083 150 (3.7) 1.03 (0.90–1.18) 0.6500
Model 4* 348 (8.7) 1.02 (0.94–1.12) 0.6211 47 (1.2) 0.93 (0.73–1.18) 0.5275 79 (2.0) 0.86 (0.72–1.03) 0.1008 149 (3.7) 1.03 (0.90–1.17) 0.7141
Model 5* 348 (8.7) 1.01 (0.93–1.10) 0.7995 47 (1.2) 0.93 (0.73–1.18) 0.5265 79 (2.0) 0.85 (0.71–1.02) 0.0896 149 (3.7) 1.02 (0.89–1.16) 0.7956
Model 0 includes legumain and randomized treatment. Model 1a includes legumain, age, sex, body mass index, diabetes mellitus, dyslipidemia, hypertension, chronic renal disease, chronic heart failure, ST elevation 
myocardial infarction/non ST elevation-acute coronary syndrome at randomization, smoking, type of acute coronary syndrome, aspirin at entry, randomized treatment, previous MI/peripheral artery disease/CABG/
percutaneous coronary intervention/nonhemorrhagic stroke. Model 1b includes the following covariates in addition to Model 1a: unfractionated heparin, low-molecular-weight heparin, use of glycoprotein IIb/IIIa inhibitor, 
statin, diuretic, and proton pump inhibitor during hospital stay. Model 1c includes the following covariates in addition to Model 1b: hemoglobin, platelets, and white blood cells. Model 2 includes the following covariates 
in addition to Model 1c: C-reactive protein. Model 3 includes the following covariates in addition to Model 2: cystatin C. Model 4 includes the following covariates in addition to Model 3: N-terminal pro−B-type natriuretic 
peptide and troponin T. Model 5 includes the following covariates in addition to Model 4: growth differentiation factor 15. All biomarkers are logarithmic transformed. CABG indicates coronary artery bypass graft; HR, 
hazard ratio; and MI, myocardial infarction.
*Multivariable Cox regression models.
†Stroke is a subset of cardiovascular death/Spontaneous MI/Stroke, procedural MI and non-CABG bleed are not.
‡Incidence during follow-up, (no. events / no. of subjects) x 100%
§The HR is per 50% increase of legumain at 1 month.
|| P value for the effect of legumain at 1 month. 
Downloaded from http://ahajournals.org by on October 5, 2020
J Am Heart Assoc. 2020;9:e016360. DOI: 10.1161/JAHA.120.016360 7
Gregersen et al Legumain in Acute Coronary Syndromes
operating at the site of acute cardiovascular events, 
but based on its dual role in inflammation, the net 
effects of this complex molecule are at present not 
clear. In fact, the lack of independent prognostic 
power of legumain in relation to the primary end point 
in the present ACS population may reflect its complex 
role in atherogenesis that most probably also depend 
on costimuli within the microenvironment.
Samples taken after 1 month were available from 
3927 patients. Whereas legumain levels at this time 
point were not associated with the primary compos-
ite end point, legumain had a negative association 
with stroke, also in the fully adjusted model. Although 
there were few patients who suffered a stroke follow-
ing 1 month (n=34) and biomarkers giving prognostic 
information when assessed after 1 month, and not 
at baseline, could be difficult to use in the clinic, this 
intriguing observation is of interest from a mecha-
nistic point of view. Although the reason for these 
seemingly contradictory findings is at present not 
clear, they could reflect the pleiotropic effects of le-
gumain, potentially promoting both plaque stabilizing 
and destabilizing effects. Future studies should elu-
cidate the dual effects of legumain on macrophages 
and the triggers for these apparently divergent ef-
fects and if these effects are of particular relevance 
to ischemic stroke.
Limitations
The current study provides deeper insights to the role 
of legumain in a large population with ACS, but has 
some limitations. The PLATO trial comprises a broad 
population with ACS, but patients requiring dialysis 
or with recent significant bleeding were not eligible. 
Furthermore, as mortality was lower in the group ran-
domized to ticagrelor, a survival bias with ticagrelor 
may have been present. Also, as legumain could exert 
its effect locally, for example inside an atherosclerotic 
plaque, the circulating levels might not reflect its func-
tions in vivo. Further studies are needed to clarify this 
relationship and if legumain is suitable to study from an 
epidemiologic point of view.
Figure 1. Kaplan-Meier estimated event rates of the 
primary outcome (composite of cardiovascular [CV] death, 
spontaneous myocardial infarction [MI], and stroke) 
per quartile of baseline legumain level during 12  months 
follow-up.
A, Cubic spline curves for legumain at baseline (ng/mL) against 
the primary and secondary outcomes (B).
Figure 2. Serum legumain levels (ng/mL) at baseline, discharge, 1 and 6 months in the whole patient group (A) and according 
to treatment groups, clopidogrel or ticagrelor (B).
Presented as median and interquartile range.
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Table 3. Effect of Legumain Levels at 1 Month Follow-Up on Subsequent Outcomes (N=3927)
Cardiovascular Death/Spontaneous  
MI/Stroke Stroke† Procedural MI Non-CABG-Related Major Bleeds
N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value|| N (%)‡ HR (95% CI)§ P Value|
Model 0* 228 (5.8) 0.89 (0.77–1.03) 0.1084 34 (0.9) 0.62 (0.44–0.88) 0.0069 25 (0.6) 1.11 (0.72–1.70) 0.6328 69 (1.8) 0.97 (0.75–1.25) 0.8140
Model 1a* 228 (5.8) 0.91 (0.79–1.05) 0.1790 34 (0.9) 0.59 (0.40–0.87) 0.0077 25 (0.6) 1.08 (0.69–1.68) 0.7395 69 (1.8) 1.01 (0.78–1.30) 0.9628
Model 1b* 228 (5.8) 0.88 (0.77–1.02) 0.0834 34 (0.9) 0.54 (0.36–0.80) 0.0025 25 (0.6) 1.07 (0.68–1.69) 0.7604 69 (1.8) 0.98 (0.76–1.27) 0.8823
Model 1c* 215 (6.0) 0.87 (0.75–1.00) 0.0537 31 (0.9) 0.59 (0.38–0.91) 0.0165 21 (0.6) 1.06 (0.65–1.74) 0.8116 64 (1.8) 0.93 (0.71–1.22) 0.5886
Model 2* 204 (6.0) 0.89 (0.77–1.04) 0.1485 31 (0.9) 0.59 (0.38–0.92) 0.0189 19 (0.6) 1.18 (0.71–1.97) 0.5250 62 (1.9) 0.91 (0.69–1.20) 0.5052
Model 3* 204 (6.0) 0.89 (0.77–1.04) 0.1440 31 (0.9) 0.59 (0.38–0.91) 0.0176 19 (0.6) 1.19 (0.71–1.98) 0.5111 62 (1.9) 0.91 (0.68–1.20) 0.5041
Model 4* 202 (6.0) 0.91 (0.78–1.06) 0.2340 31 (0.9) 0.57 (0.37–0.88) 0.0111 19 (0.6) 1.29 (0.76–2.17) 0.3476 62 (1.9) 0.91 (0.69–1.21) 0.5145
Model 5* 202 (6.0) 0.90 (0.77–1.05) 0.1825 31 (0.9) 0.57 (0.37–0.88) 0.0114 19 (0.6) 1.30 (0.77–2.20) 0.3289 62 (1.9) 0.89 (0.67–1.18) 0.4157
Model 0 includes legumain at 1 month, adjusted for baseline legumain and randomized treatment. Model 1a includes legumain at 1 month, adjusted for baseline legumain, age, sex, body mass index, diabetes mellitus, 
dyslipidemia, hypertension, chronic renal disease, chronic heart failure, ST elevation myocardial infarction/non ST elevation-acute coronary syndrome at randomization, smoking, type of acute coronary syndrome, 
aspirin at entry, randomized treatment, previous (MI/periphery artery disease/CABG/percutaneous coronary intervention/nonhemorrhagic stroke). Model 1b includes the following covariates in addition to Model 1a: 
unfractionated heparin, low-molecular-weight heparin, glycoprotein IIb/IIIa inhibitor, statin, diuretic, and proton pump inhibitor during hospital stay. Model 1c includes the following covariates in addition to Model 1b: 
hemoglobin, platelets, and white blood cells. Model 2 includes the following covariates in addition to Model 1c: C-reactive protein. Model 3 includes the following covariates in addition to Model 2: cystatin C. Model 4 
includes the following covariates in addition to Model 3: N-terminal pro−B-type natriuretic peptide and troponin T. Model 5 includes the following covariates in addition to Model 4: growth differentiation factor 15. All 
adjustment biomarkers are at baseline, included in the models after logarithmic transformation. CABG indicates coronary artery bypass graft; HR, hazard ratio; and MI, myocardial infarction.
*Multivariable Cox regression models.
†Stroke is a subset of cardiovascular Death/Spontaneous MI/Stroke, procedural MI and non-CABG bleed are not. 
‡Incidence during follow-up, (no. events / no. of subjects) x 100%
§The HR is per 50% increase of legumain at 1 month.
||P value for the effect of legumain at 1 month.
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CONCLUSIONS
Legumain was associated with outcome in patients 
with ACS but not in the fully adjusted model. The asso-
ciation between high levels of legumain at 1 month and 
decreased occurrence of stroke could be of interest 
from a mechanistic point of view, illustrating the com-
plex and potential dual role of legumain during ACS 
and atherogenesis.
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Data S1. 
Supplemental Methods 
Sampling and laboratory analysis 
Baseline venous blood samples were obtained within 24 hours of admission, prior to the 
administration of study medication. The venous blood was centrifuged and plasma and serum 
samples locally frozen in aliquots and stored at -70ºC in a central repository in Uppsala Biobank 
until analyses. Serum legumain concentrations were determined with sandwich immunoassay 
from R&D Systems (Duoset DY4769), Stillwater, MN. Total and differential (i.e., neutrophils, 
lymphocytes and monocytes) white blood cell (WBC) counts, hemoglobin (Hb) and plasma C-
reactive protein (CRP) were analyzed at the UCR laboratory, Uppsala, Sweden with a 
spectrophotometric analysis (Architect, Abbott). Platelet count was determined using an 
Electronic Cell Counter by Quintiles Laboratories. Plasma high sensitivity cardiac troponin T 
(hs-troponin T; TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cystatin C 
were determined with sandwich immunoassays on the Cobas® Analytics e601 Immunoanalyzer 
(Roche Diagnostics, Mannheim, Germany). Plasma growth/differentiation factor (GDF)-15 was 
measured with a pre-commercial assay (Roche Diagnostics) using a monoclonal mouse antibody 
for capture and a monoclonal mouse antibody fragment for detection in a sandwich assay format. 
We also include data on sCD40L, sP-selectin, D-dimer, IL-6 and oxidized LDL (oxLDL), 
analyzed as previously described20-22. The results of these analyses in relation to outcomes and 
effects of study treatment have previously been reported20-25.  
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Table S1. Baseline characteristics of patients in the total PLATO population and in the 
current study sub-population. 
Group of 
characteristics Characteristic 
PLATO total population 
N=18421 
Legumain population 
(Biomarker substudy) 
N=4883 
Demographics Age yrs 62 (54-71) 62 (54-71) 
Female 5237 (28.4%) 1467 (30.0%) 
Weight, kg 80 (70-90) 80 (70-90) 
BMI, kg/m2 27.4 (24.7-30.4) 27.7 (25.0-30.6) 
Risk factor Habitual smoker 6613 (35.9%) 1781 (36.5%) 
Hypertension 12047 (65.4%) 3228 (66.1%) 
Dyslipidemia 8593 (46.7%) 2057 (42.1%) 
Diabetes mellitus 4621 (25.1%) 1099 (22.5%) 
Medical history Angina pectoris 8277 (44.9%) 2278 (46.7%) 
Myocardial infarction 3784 (20.5%) 965 (19.8%) 
Congestive heart failure 1041 (5.7%) 284 (5.8%) 
PCI 2456 (13.3%) 607 (12.4%) 
CABG 1092 (5.9%) 242 (5.0%) 
TIA 495 (2.7%) 113 (2.3%) 
Non-hemorrhagic stroke 710 (3.9%) 165 (3.4%) 
Peripheral arterial disease 1128 (6.1%) 335 (6.9%) 
Chronic renal disease 775 (4.2%) 172 (3.5%) 
Type of ACS ST-elevation MI 7471 (40.6%) 2185 (44.7%) 
Risk scores TIMI risk score  4.0 (2.0-5.0) 4.0 (2.0-5.0) 
GRACE risk score 133 (117-152) 133 (117-151) 
Anti-thrombotic 
treatment in 
hospital 
Aspirin 17906 (97.2%) 4801 (98.3%) 
Unfractioned heparin 10661 (57.9%) 2659 (54.5%) 
LMW heparin 9581 (52.0%) 2642 (54.1%) 
Fondaparinux 505 (2.7%) 73 (1.5%) 
Bivalirudin 371 (2.0%) 75 (1.5%) 
GPIIb/IIIa inhibitor 5003 (27.2%) 1271 (26.0%) 
Other medication 
in hospital 
Beta-blocker 15810 (85.8%) 4254 (87.1%) 
ACE-inhibitor and/or ARB 15351 (83.3%) 4237 (86.8%) 
Cholesterol lowering drug (statin) 17319 (94.0%) 4563 (93.4%) 
Ca-inhibitor 3984 (21.6%) 1028 (21.1%) 
Diuretic 6906 (37.5%) 1847 (37.8%) 
Proton pump inhibitor 8490 (46.1%) 2126 (43.5%) 
Biomarkers Troponin T, ng/L 191.0 (45.4-654.0) 159.0 (39.8-549.5) 
NT-proBNP, pmol/L 460.0 (149.0-1300) 420.0 (135.0-1150) 
Cystatin C, mg/L 0.83 (0.68-1.01) 0.82 (0.67-1.00) 
GDF-15, ng/mL 1550 (1145-2219) 1535 (1146-2152) 
CRP, mg/L 3.7 (1.6-9.5) 3.5 (1.6-8.8) 
IL-6, ng/mL 3.4 (1.9-7.3) 3.4 (1.9-7.3) 
Continuous variables are expressed median (interquartile range). Categorical variables are expressed as frequency 
(%). p-values from the Chi-square test (categorical variables) or Kruskal-Wallis test (continuous variables). BMI, 
body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; TIA, transient 
ischemic attack; MI, myocardial infarction; TIMI, thrombolysis in myocardial infarction; GRACE, global registry of 
acute coronary events; LMW, low-molecular-weight; ACE, angiotensin-converting enzyme; ARB, angiotensin-
receptor blockers; NT-proBNP, N-WHUPLQDOSURí%-type natriuretic peptide, GDF-15, growth differentiation factor 15; 
CRP; C-reactive protein.
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Table S2. Multivariable effect of baseline characteristics and biomarkers on legumain 
levels at baseline. 
Background characteristic 
Relative 
change 95% C.I. p value 
Age, 10 year increase 0.9359 (0.9169 ; 0.9552) <.0001 
STEMI 0.9146 (0.8799 ; 0.9506) <.0001 
GPIIb/IIIa inhibitor 0.9199 (0.8834 ; 0.9579) <.0001 
GDF-15, 10% increase 1.0108 (1.0068 ; 1.0147) <.0001 
Platelet count, 10% increase 1.0287 (1.0220 ; 1.0354) <.0001 
hsCRP, 10% increase 1.0029 (1.0014 ; 1.0044) 0.0002 
IL-6, 10% increase 1.0047 (1.0022 ; 1.0072) 0.0002 
Hb, 10% increase 1.0316 (1.0151 ; 1.0483) 0.0002 
WBC, 10% increase 0.9891 (0.9833 ; 0.9950) 0.0003 
Chronic renal disease 0.8451 (0.7669 ; 0.9312) 0.0007 
NT-proBNP, 10% increase 1.0026 (1.0010 ; 1.0042) 0.0014 
sCD40L, 10% increase 1.0023 (1.0008 ; 1.0037) 0.0025 
Dyslipidemia 0.9483 (0.9147 ; 0.9832) 0.0040 
Female sex 0.9474 (0.9084 ; 0.9882) 0.0120 
Unfractioned heparin 0.9560 (0.9216 ; 0.9915) 0.0157 
Proton pump inhibitor 0.9591 (0.9264 ; 0.9929) 0.0182 
Diabetes 1.0496 (1.0059 ; 1.0952) 0.0258 
LMW heparin 1.0431 (1.0048 ; 1.0828) 0.0269 
PAD 1.0736 (1.0022 ; 1.1500) 0.0431 
Cholesterol lowering (statin) 0.9254 (0.8556 ; 1.0008) 0.0523 
Myocardial infarction 1.0499 (0.9989 ; 1.1035) 0.0551 
Diuretic 1.0352 (0.9967 ; 1.0752) 0.0736 
Aspirin at admission 0.9211 (0.8341 ; 1.0172) 0.1044 
Hypertension 1.0287 (0.9901 ; 1.0689) 0.1465 
CABG 1.0573 (0.9728 ; 1.1490) 0.1896 
sP-selectin, 10% increase 1.0022 (0.9988 ; 1.0056) 0.2117 
CHF 1.0492 (0.9700 ; 1.1348) 0.2305 
Habitual smoker 1.0189 (0.9790 ; 1.0604) 0.3589 
Troponin (hs-cTn), 10% increase 0.9995 (0.9984 ; 1.0006) 0.3970 
Ox-LDL, 10% increase 0.9984 (0.9940 ; 1.0028) 0.4747 
BMI, t 30 kg/m2 1.0079 (0.9700 ; 1.0472) 0.6887 
Cystatin C, 10% increase 0.9993 (0.9935 ; 1.0051) 0.8003 
Non-haemorrhagic stroke 1.0102 (0.9236 ; 1.1048) 0.8250 
D-dimer, 10% increase 0.9999 (0.9974 ; 1.0024) 0.9410 
PCI 0.9993 (0.9405 ; 1.0618) 0.9826 
Linear model for log-transformed legumain. The relative increase is the adjusted geometric mean ratio between 
subgroups or for the stated change in continuous variables. STEMI, ST-segment elevation myocardial infarction; 
GPIIb/IIIa, glycoprotein GPIIb/IIIa; GDF-15, growth differentiation factor 15; CRP; C-reactive protein; Hb, 
hemoglobin; WBC, white blood cells; NT-proBNP, N-WHUPLQDOSURí%-type natriuretic peptide, LMW, low-
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molecular-weight; PAD, peripheral artery disease; CABG, coronary artery bypass graft; CHF, chronic heart failure,  
Ox-LDL, oxidized low density lipoprotein, BMI, body mass index; PCI, percutaneous coronary intervention. 
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Figure S1. Restricted cubic-spline of the interaction between baseline legumain levels and 
the primary outcome (composite of cardiovascular death (CV), spontaneous myocardial 
infarction, and stroke) of the two treatment groups; clopidogrel or ticagrelor.  
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Figure S2. Cubic spline curves for legumain levels at one month against the primary and 
secondary outcomes. 
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